Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV.

IF 3.6 3区生物学 Q2 MYCOLOGY

Mycopathologia Pub Date : 2024-08-01 DOI:10.1007/s11046-024-00871-0

Stella Wolfgruber, Sarah Sedik, Lena Klingspor, Annamaria Tortorano, Neil A R Gow, Katrien Lagrou, Jean-Pierre Gangneux, Johan Maertens, Jacques F Meis, Cornelia Lass-Flörl, Sevtap Arikan-Akdagli, Oliver A Cornely, Martin Hoenigl

{"title":"Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV.","authors":"Stella Wolfgruber, Sarah Sedik, Lena Klingspor, Annamaria Tortorano, Neil A R Gow, Katrien Lagrou, Jean-Pierre Gangneux, Johan Maertens, Jacques F Meis, Cornelia Lass-Flörl, Sevtap Arikan-Akdagli, Oliver A Cornely, Martin Hoenigl","doi":"10.1007/s11046-024-00871-0","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive candidiasis and candidemia remain a significant public health concern. The European Confederation of Medical Mycology (ECMM) conducted three pan-European multicentre studies from 1997 to 2022 to investigate various aspects of invasive Candida infections. These studies revealed shifting trends in Candida species distribution, with an increase of non-albicans Candida species as causative pathogens, increasing rates of antifungal resistance, and persistently high mortality rates. Despite advancements in antifungal treatment, the persistently high mortality rate and increasing drug resistance, as well as limited drug access in low-income countries, underscore the need for continued research and development in the treatment of Candida infections. This review aims to summarize the findings of the three completed ECMM Candida studies and emphasize the importance of continued research efforts. Additionally, it introduces the upcoming ECMM Candida IV study, which will focus on assessing candidemia caused by non-albicans Candida species, including Candida auris, investigating antifungal resistance and tolerance, and evaluating novel treatment modalities on a global scale.</p>","PeriodicalId":19017,"journal":{"name":"Mycopathologia","volume":"189 4","pages":"70"},"PeriodicalIF":3.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11294264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mycopathologia","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1007/s11046-024-00871-0","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Invasive candidiasis and candidemia remain a significant public health concern. The European Confederation of Medical Mycology (ECMM) conducted three pan-European multicentre studies from 1997 to 2022 to investigate various aspects of invasive Candida infections. These studies revealed shifting trends in Candida species distribution, with an increase of non-albicans Candida species as causative pathogens, increasing rates of antifungal resistance, and persistently high mortality rates. Despite advancements in antifungal treatment, the persistently high mortality rate and increasing drug resistance, as well as limited drug access in low-income countries, underscore the need for continued research and development in the treatment of Candida infections. This review aims to summarize the findings of the three completed ECMM Candida studies and emphasize the importance of continued research efforts. Additionally, it introduces the upcoming ECMM Candida IV study, which will focus on assessing candidemia caused by non-albicans Candida species, including Candida auris, investigating antifungal resistance and tolerance, and evaluating novel treatment modalities on a global scale.

Abstract Image

查看原文本刊更多论文

三项关于侵袭性念珠菌感染的泛欧洲多中心研究的启示以及对 ECMM 念珠菌 IV 的展望。

侵袭性念珠菌病和念珠菌血症仍然是一个重大的公共卫生问题。欧洲医学真菌学联合会（ECMM）在 1997 年至 2022 年期间开展了三项泛欧洲多中心研究，以调查侵袭性念珠菌感染的各个方面。这些研究揭示了念珠菌物种分布的变化趋势，非阿氏念珠菌物种作为致病病原体的数量增加，抗真菌耐药率上升，死亡率居高不下。尽管抗真菌治疗取得了进展，但死亡率居高不下、耐药性不断增加以及低收入国家药物供应有限等问题，都凸显了继续研究和开发念珠菌感染治疗方法的必要性。本综述旨在总结三项已完成的 ECMM 念珠菌研究的结果，并强调继续开展研究工作的重要性。此外，它还介绍了即将开展的 ECMM 念珠菌 IV 研究，该研究将重点评估由包括白色念珠菌在内的非阿氏杆菌念珠菌引起的念珠菌血症，调查抗真菌耐药性和耐受性，并在全球范围内评估新型治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mycopathologia 生物-真菌学

CiteScore

6.80

自引率

3.60%

发文量

审稿时长

3 months

期刊介绍： Mycopathologia is an official journal of the International Union of Microbiological Societies (IUMS). Mycopathologia was founded in 1938 with the mission to ‘diffuse the understanding of fungal diseases in man and animals among mycologists’. Many of the milestones discoveries in the field of medical mycology have been communicated through the pages of this journal. Mycopathologia covers a diverse, interdisciplinary range of topics that is unique in breadth and depth. The journal publishes peer-reviewed, original articles highlighting important developments concerning medically important fungi and fungal diseases. The journal highlights important developments in fungal systematics and taxonomy, laboratory diagnosis of fungal infections, antifungal drugs, clinical presentation and treatment, and epidemiology of fungal diseases globally. Timely opinion articles, mini-reviews, and other communications are usually invited at the discretion of the editorial board. Unique case reports highlighting unprecedented progress in the diagnosis and treatment of fungal infections, are published in every issue of the journal. MycopathologiaIMAGE is another regular feature for a brief clinical report of potential interest to a mixed audience of physicians and laboratory scientists. MycopathologiaGENOME is designed for the rapid publication of new genomes of human and animal pathogenic fungi using a checklist-based, standardized format.